Randomized trial of gefitinib with and without pemetrexed as first-line therapy in East-Asian patien

来源 :第十八届全国临床肿瘤学大会暨2015年CSCO学术年会 | 被引量 : 0次 | 上传用户：jiangyang0121

【摘要】

：

目的： Pemetrexed (P) is the standard of care for non-squamous non-small cell lung cancer (NS NSCLC)， whereas epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs)， such as gefitinib

【作者】

：

Ying Cheng Haruyasu Murakami Pan-Chyr Yang Jianxing He Kazuhiko Nakagawa Jin Hyoung Kang Joo-Hang Kim Tarun Puri Xin Wang Sotaro Enatsu James Chih-Hsin Yang

【机构】

：

changchun Jilin Provincial Cancer Hospital, Changchun, China

【出处】

：

第十八届全国临床肿瘤学大会暨2015年CSCO学术年会

【发表日期】

：

2015年4期

【关键词】

：

Non-squamous non-small cell lung cancer Pemetrexed

下载到本地 , 更方便阅读

下载此文赞助VIP

声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架

论文部分内容阅读

其他文献

扩张后皮瓣修复四肢瘢痕挛缩

目的：探讨四肢瘢痕的修复方法。方法：在四肢正常皮肤与瘢痕交界处或瘢痕上做切口，在正常皮肤的深筋膜下置入扩张囊，扩张阀门外置。术后3天拔除引流管在医生指导下患者自行扩张囊注液扩张。待扩张完全后，将四肢瘢痕切除，设计直接推进皮瓣或易位皮瓣修复四肢瘢痕切除创面。术后常规应用激素类药物促进皮瓣静脉回流减轻水肿，防止皮瓣血运障碍。术后常规抗瘢痕治疗。结果：本组30例，采用扩张后皮瓣修复四肢瘢痕切除后创面，达

会议

四肢瘢痕扩张术

扩张后上臂内侧皮瓣修复额部瘢痕

目的：探讨额部瘢痕切除后创面的修复方法。方法：按逆行设计原则，在患者上臂内侧无瘢痕、肩关节、颈部活动无受限的情况，在上臂外侧做切口，置入扩张囊，超量注水后，在充分考虑瘢痕切除、松解后创面大小，及扩张皮瓣回缩等问题，先行拟转移皮瓣延迟术。术后7天行额部瘢痕切除，皮瓣带蒂转移术。再3周后行皮瓣断蒂、舒平修复额部瘢痕切除后剩余创面。结果：本组7例，均采用扩张后上臂内侧皮瓣带蒂转移术。术后皮瓣无血运障碍，

会议

上臂内侧皮瓣扩张术额部瘢痕

口内纵型“川”字切口假体隆颏术

目的：探求一种通过口内纵型"川"字切口使假体置入更加方便、定位准确及减少术后并发症的隆颏手术新入路。方法：根据颏部解剖特点，采用口内双侧粘膜纵型切口及正中观察切口，假体从两侧切口置入后其上方正中的V型标记正对观察切口，检查无出血即可缝合。结果：19例患者，切口均Ⅰ期愈合，未出现明显术后并发症，随访6-12个月，效果满意。结论：采用经口内纵型"川"字切口进行隆颏矫正MccarthyⅠ型轻度小颏畸形，

会议

鼻咽癌IMRT治疗后腮腺区域失败分析

目的：讨论鼻咽癌IMRT后，腮腺区域复发的潜在原因。方法：回顾我院2005年1月至2012年12月鼻咽癌IMRT患者1096例，腮腺复发13例，可分析的腮腺复发12例。以腮腺区域复发侧为病例组，以腮腺区域未复发侧为对照组，进行病例对照研究。

会议

鼻咽癌腮腺失败病因分析病例对照

Three different clinical processes of slow-growing intrathoracic disseminated lung cancer

Objective: The progression of pulmonary ground glass nodules (GGNs) was slow, 5 years survival rate of lobe/sublobe resection was close to 100%.In clinical, we also found that the progression of some

会议

intrathoracic disseminatedslow growing

Moderate dose-fractionated stereotactic body radiotherapy for medically Inoperable stage Ⅰ non-small

Objective: To investigate the clinical outcomes and toxicity of stereotactic body radiotherapy (SBRT) with amoderate dose fraction for medically inoperable stage Ⅰ non-small cell lung cancer (NSCLC).

会议

Stereotactic body radiotherapynon-small cell lung

Circulating Tumor Cells and Evaluation of Targeted Therapy Effect in EGFR Mutation/ALK Translocation

Objective: Targeted therapies have considerably improved the prognosis of patients with non-small cell lung cancer (NSCLC).Although not precision enough, RESIST criteria was still the most often used

会议

Circulating Tumor CellsTargeted TherapyMetastati

Phase Ⅲ trial of afatinib vs erlotinib in patients (pts) with squamous cell carcinoma (SCC) of the l

Objective: Treatment options for pts with advanced SCC of the lung progressing after platinum-based chemotherapy are limited.Over expression of EGFR, other ErbB receptors and the dysregulation of thei

会议

afatiniberlotinibsquamous cell carcinoma

Predictive and prognostic value of de novo MET expression in patients with advanced non-small cell l

Objective: The cellular-mesenchymal-epithelial transition protein (MET) has recently been identified as a novel promising target in non-small-cell lung cancer (NSCLC) treatment.

会议

Non-small cell lung cancerMETChemothrapy

Abundance of EGFR Mutations affects the efficacy of EGFR-TKI in patients with EGFR-Mutant advanced l

Objective: The discovery of epidermal growth factor receptor(EGFR) mutations in NSCLC opened the era of individualized therapy.A number of clinical studies have shown the efficacy of EGFR-tyrosine kin

会议

lung adenocarcinomaEpidermal growth factor recept

Randomized trial of gefitinib with and without pemetrexed as first-line therapy in East-Asian patien

其他学术论文